MDXG

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sanara MedTech Inc. (NasdaqCM: SMTI) to MiMedx Group, Inc. (NasdaqCM: MDXG). Under the terms of the proposed transaction, shareholders of Sanara will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for each share of Sanara that they own. KSF is seeking to determine whether this c.

MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript

Reports  Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026.

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX's Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX's Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga. and FORT WORTH, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Sanara MedTech Inc. (“Sanara,” “Sanara MedTech”) (Nasdaq: SMTI) today announced that they have entered into a definitive merger agreement under which MIMEDX will acquire all of the outstanding shares of Sanara in a cash and stock transaction valued at $35 per Sanara share with a total enterprise value of approximately $350 million.

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026.

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Investors need to pay close attention to MDXG stock based on the movements in the options market lately.

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide.